Oncolytics Biotech (TSX:ONC) - Cotización, noticias y análisis

Resumen de acción ONC

Oncolytics Biotech Inc, empresa biofarmacéutica en fase clínica, se centra en el descubrimiento y desarrollo de productos farmacéuticos para el tratamiento del cáncer.

Acerca de la empresa

ONC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 96.9% por debajo de nuestra estimación de su valor justo

Análisis de riesgos

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares (CA$0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de Oncolytics Biotech Inc.

Sernova

TSX:SVA

CA$112.3m

Eupraxia Pharmaceuticals

TSX:EPRX

CA$141.1m

Medicenna Therapeutics

TSX:MDNA

CA$184.7m

Satellos Bioscience

TSX:MSCL

CA$53.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Oncolytics Biotech
Historical stock prices
Current Share Price	CA$1.59
52 Week High	CA$4.49
52 Week Low	CA$1.20
Beta	1.45
1 Month Change	3.25%
3 Month Change	12.77%
1 Year Change	-27.73%
3 Year Change	-52.11%
5 Year Change	-31.76%
Change since IPO	-88.84%

Noticias y actualizaciones recientes

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Feb 23

Recent updates

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31

Rentabilidad de los accionistas

	ONC	CA Biotechs	Mercado CA
7D	-1.2%	1.1%	1.3%
1Y	-27.7%	-36.3%	9.1%

Rentabilidad vs. Industria: ONC superó al sector Canadian Biotechs , que obtuvo un rendimiento del -36.8% el año pasado.

Rentabilidad vs. Mercado: ONC obtuvo unos resultados inferiores a los del mercado Canadian, que fue del 5.5% el año pasado.

Volatilidad de los precios

Is ONC's price volatile compared to industry and market?
ONC volatility
ONC Average Weekly Movement	9.4%
Biotechs Industry Average Movement	11.7%
Market Average Movement	8.8%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	3.1%

Precio estable de las acciones: ONC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ONC (11%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1998	29	Matt Coffey	www.oncolyticsbiotech.com

Oncolytics Biotech Inc, empresa biofarmacéutica en fase clínica, se dedica al descubrimiento y desarrollo de productos farmacéuticos para el tratamiento del cáncer. La empresa está desarrollando pelareorep, un agente inmunoterapéutico administrado por vía intravenosa, que se encuentra en ensayos clínicos de fase 3 para el tratamiento del cáncer de mama metastásico con receptores hormonales positivos / factor de crecimiento epidérmico humano 2 negativo y del adenocarcinoma ductal pancreático avanzado / metastásico. Tiene un acuerdo de codesarrollo con Merck KGaA y Pfizer Inc. para codesarrollar pelareorep, así como con Roche Holding AG.

Resumen de fundamentos de Oncolytics Biotech Inc.

¿Cómo se comparan los beneficios e ingresos de Oncolytics Biotech con su capitalización de mercado?
Estadísticas fundamentales de ONC
Capitalización bursátil	CA$119.92m
Beneficios(TTM)	-CA$28.21m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-4.3x

Ratio precio-beneficio (PE)

¿Está ONC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ONC
Ingresos	CA$0
Coste de los ingresos	CA$0
Beneficio bruto	CA$0
Otros gastos	CA$28.21m
Beneficios	-CA$28.21m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.37
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ONC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ONC

Recompensas

Análisis de riesgos

Competidores de Oncolytics Biotech Inc.

TSX:SVA

CA$112.3m

TSX:EPRX

CA$141.1m

TSX:MDNA

CA$184.7m

TSX:MSCL

CA$53.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New minor risk - Profitability

Recent updates

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Oncolytics Biotech Inc. Announces Selection of Pelareorep for Inclusion as New Investigational Treatment in Precision Promise, an Innovative Adaptive Phase 3 Clinical Trial

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS

Consensus EPS estimates upgraded to CA$0.43 loss

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 20%

Price target decreased by 14% to CA$6.50

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting

Price target decreased to CA$6.21

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Independent Director recently bought CA$56k worth of stock

Consensus forecasts updated

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Oncolytics Biotech Inc. Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with Chimeric Antigen Receptor T Cell Therapy in Solid Tumors

Oncolytics Biotech Inc. Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer

No longer forecast to breakeven

Oncolytics Biotech® Inc. Provides Positive Safety Update on Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech Inc. Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

No longer forecast to breakeven

Oncolytics Biotech Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

No longer forecast to breakeven

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-Of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Oncolytics Biotech Inc., Annual General Meeting, May 07, 2021

Oncolytics Biotech Inc. Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Price target raised to CA$10.13

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New 90-day high: CA$3.40

Oncolytics Biotech Announces Positive Clinical Results against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting